Biotechnology
News Category
Instinct Bio Partners With INVITRX to Launch GENREVER in U.S. and Boost Indonesia Regenerative Medicine
Instinct Bio's collaboration with INVITRX aims to bring its GENREVER cosmetic brand to the U.S. market and support regenerative medicine initiatives i...
BRAIN Biotech AG Appoints Dr. Sven K. Weber as New CEO, Succeeding Adriaan Moelker
Dr. Sven K. Weber will become CEO of BRAIN Biotech AG on October 1, 2026, succeeding Adriaan Moelker, who retires after six years; this leadership cha...
VERAXA Biotech Expands Patent Portfolio to Protect Next-Generation Cancer Therapy Platforms
VERAXA Biotech (VRXA) filed new patent applications in 2025, expanding its portfolio to over 50 granted patents across 14 countries, aiming to protect...
MindBio Therapeutics Delivers First Edge AI Kiosks for Workplace Impairment Screening
MindBio Therapeutics has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, aiming to provide rapid, scala...
VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC(R) Cancer Therapy Platform
VERAXA Biotech strengthens its scientific leadership with Dr. Christoph Erkel as CSO, advancing its proprietary BiTAC(R) platform toward clinical deve...
VERAXA Biotech Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
VERAXA Biotech AG has expanded its intellectual property portfolio with new patent filings for its BiTAC-TCE and BiTAC-ADC platforms, strengthening it...
Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Technology Targeting Neurodegenerative Diseases
Greenland Mines (GRML) received a Canadian patent for Klotho-based gene therapies targeting Alzheimer's, Parkinson's, ALS, and multiple sclerosis, exp...
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials While Expanding Commercial Revenue Streams
Quantum BioPharma's executive outlines the development strategy for Lucid-MS, a potential multiple sclerosis treatment entering Phase 2 trials, alongs...
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures
VERAXA Biotech shareholders approved proposals to enhance corporate flexibility for growth, including a capital band and expanded board, with over 99....
Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Technology
Greenland Mines Ltd. received a Canadian patent for Klotho-based gene therapies targeting neurodegenerative diseases, expanding its IP portfolio and a...
NanoViricides Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
NanoViricides seeks regulatory approval to begin a Phase II trial of its oral NV-387 gummies for Bundibugyo ebolavirus in the DRC, where no approved t...
Lantern Pharma's LP-184 Cleared by EMA for Bladder Cancer Trial in Europe
The EMA clearance allows Lantern Pharma to initiate a biomarker-guided Phase 1b/2 trial of LP-184 in advanced bladder cancer patients, advancing its A...
GeoVax Reports Second Quarter 2026 Financial Results and Advances GEO-MVA Toward Pivotal Immunobridging Study
GeoVax Labs reports progress on its GEO-MVA vaccine program toward a pivotal immunobridging study under an expedited regulatory pathway, while advanci...
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration
VERAXA Biotech announces the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completes discovery work, moving the c...
Quantum BioPharma Advances Lucid-MS and Commercial Products, Executive Details Strategy in Podcast
Quantum BioPharma's executive outlines plans for Lucid-MS Phase 2 trial and commercial growth with unbuzzd, highlighting a dual strategy combining cli...
Onco-Innovations Advances ONC010 Toward Clinical Studies, Strengthening Its Oncology Pipeline
Onco-Innovations is progressing its lead cancer drug candidate ONC010, a PNKP inhibitor, by scaling up manufacturing and establishing partnerships to ...
Tonix Pharmaceuticals to Report Second-Quarter 2026 Financial Results on August 10
Tonix Pharmaceuticals announced it will release second-quarter 2026 financial results and operational highlights, followed by a conference call, provi...
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration
VERAXA Biotech AG announced the advancement of its bispecific antibody-drug conjugate program VXA-222 following a key technical milestone in its colla...
Onco-Innovations Integrates PNKP Inhibition, Nanoparticle Delivery, and AI to Address Key Cancer Drug Development Challenges
Onco-Innovations Ltd. is advancing its lead candidate ONC010, a PNKP inhibitor combined with a nanoparticle delivery system, while leveraging AI throu...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as chief scientific officer, leveraging his two decades of antibody therapeutics experience to dri...
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC®-TCE Program
VERAXA Biotech's receipt of Scientific Advice from Germany's Paul-Ehrlich-Institute supports its development strategy for its lead BiTAC®-TCE candidat...
Onco-Innovations Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum
Onco-Innovations Ltd. is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor for biomarker-selected cancers, aligning with the shift toward ...
Lantern Pharma Secures U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment
Lantern Pharma received a U.S. patent allowance for methods using a three-gene biomarker signature to select patients for LP-184 therapy, advancing pr...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech has appointed Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor therapies, signaling a strategic push to...
BioAdaptives Completes Manufacturing Readiness for Upcoming Wellness Product Launch
BioAdaptives has finalized commercial manufacturing and supply chain logistics, paving the way for the launch of its MyndSystem and Xcellara wellness ...
iOrganBio Appoints Stem Cell Authority Lee L. Rubin, Ph.D., to Scientific Advisory Board
iOrganBio strengthens its Scientific Advisory Board with the appointment of Lee L. Rubin, Ph.D., a leading expert in stem cell biology and translation...
Creative Biolabs Expands Microfluidics Solutions for High-Throughput Antibody Discovery
Creative Biolabs has expanded its integrated microfluidics portfolio to accelerate high-throughput antibody discovery, addressing challenges in screen...
Quantum BioPharma Develops Dual Strategy Against MS and Alcohol-Induced Brain Impairment
Quantum BioPharma is advancing a two-pronged pipeline targeting multiple sclerosis with Lucid-MS and alcohol intoxication with unbuzzd, addressing sig...
Oncotelic Therapeutics Publishes Preclinical Data Supporting Intravenous Cancer Therapy Sapu003
The publication of preclinical data for Sapu003, an intravenous formulation of everolimus, highlights its potential to overcome oral drug limitations ...
Kairos Pharma Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer
Kairos Pharma has partnered with Bayer to test its antibody ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer, ai...
VERAXA Biotech Advances BiTAC-TCE Program with Positive Regulatory Feedback from Germany's PEI
VERAXA Biotech received Scientific Advice from the Paul-Ehrlich-Institute supporting its BiTAC-TCE development strategy, reducing uncertainty before c...
VivoSim Labs Raises $4 Million in Private Placement with Healthcare-Focused Investor
VivoSim Labs secures $4 million through a private placement to fund working capital and general corporate purposes, signaling investor confidence in i...
Greenwich LifeSciences Reports Progress in Phase 3 Trial for Breast Cancer Immunotherapy GLSI-100
Greenwich LifeSciences announced DSB recommendation to continue its Phase 3 FLAMINGO-01 trial for GLSI-100, with planned expansions including up to 2,...
Quantum BioPharma Develops Two-Pronged Attack on Brain Disorders Affecting Millions
Quantum BioPharma is advancing two programs—Lucid-MS for multiple sclerosis and unbuzzd for alcohol intoxication—to address significant unmet neurolog...
American Fusion Inc. Secures Texas Certificate of Registration for Fusion Engine Testing
American Fusion Inc. received a Texas DSHS Certificate of Registration for Industrial Radiation Machines, enabling testing of its Texatron Fusion Engi...
Large WHO Study Finds No Link Between Mobile Phones and Brain Cancer
A comprehensive review commissioned by the World Health Organization found no evidence that mobile phone use causes brain cancer, addressing long-stan...
Quantum BioPharma Reaches Halfway Point in MS Imaging Study with Encouraging Early Data
Quantum BioPharma announced that its PET imaging study for multiple sclerosis has enrolled half the patients and shown promising preliminary results, ...
GeoVax GEO-MVA Platform Aligns with HHS/ASPR Five-Year Preparedness Strategy
GeoVax highlights how its GEO-MVA vaccine platform aligns with ASPR's $66.9 billion five-year strategy emphasizing domestic manufacturing, platform te...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform, Advancing Toward Clinical Trials
VERAXA Biotech announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute on its BiTAC-TCE platform, supporting its development stra...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech announced receipt of Scientific Advice from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE program, providing clarity on the d...
Regentis Biomaterials Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Regentis Biomaterials announced a Japan patent allowance for its GelrinC manufacturing technology, strengthening its IP portfolio and positioning in t...
MindBio Therapeutics Advances Voice-Based AI Tech for Real-Time Impairment Detection
MindBio Therapeutics is developing an AI-powered voice analysis platform to detect drug and alcohol impairment from short speech samples, offering a n...
Gut Microbial Metabolites Linked to Improved Cancer Immunotherapy Responses
New research identifies metabolites from gut bacteria that enhance cancer immunotherapy effectiveness, with implications for developing microbiome-bas...
SS Innovations Appoints Veteran Medtech Finance Executive as CFO Amid Global Expansion
SS Innovations International appoints Sarah M. Romano as CFO, leveraging her capital markets expertise to support global expansion and FDA clearance e...
Creative Biolabs Integrates Microfluidics and Electrochemical Biosensors to Accelerate Next-Generation POCT Diagnostics
Creative Biolabs has unified microfluidics and electrochemical biosensors to provide a scalable platform for developing next-generation point-of-care ...
BioAdaptives Details Xcellara Platform Strategy Ahead of XcellaraHeart Launch
BioAdaptives outlines the scientific strategy for its Xcellara cellular wellness platform, which combines a clinically proven stem cell mobilization b...
NeuroOne Expands Drug Delivery Program Through Mayo Collaboration on Pediatric Brain Cancer Trial
NeuroOne Medical Technologies partners with Mayo Clinic on a CCRF-funded study using its drug delivery neural device to enhance intratumoral drug rete...
Oncotelic Therapeutics Debuts AI-Powered Manufacturing Platform for Biotech Firms
Oncotelic Therapeutics launched an AI-GMP manufacturing platform combining its PDAOAI architecture with TechForce Robotics' automation to help emergin...